Junshi生物科学公司2024年收入猛增30%,主要药物Tripalimab推动增长。 Junshi Biosciences saw a 30% revenue jump in 2024, with key drug toripalimab driving growth.

Junshi生物科学组织报告说,2024年收入增长了30%,达到19.48亿元,其主要产品Toripalimab为这一增长做出了重大贡献。 Junshi Biosciences reported a 30% rise in revenue to RMB1,948 million in 2024, with its key product, toripalimab, contributing significantly to this growth. 由于采取了节省成本的措施,研究和开发费用下降了34%,降至12.75亿元。 Research and development expenses dropped by 34% to RMB1,275 million due to cost-saving measures. 该公司的损失减少了44%,减至12.282亿元,现金状况改善,增至29.17亿元。 The company's loss decreased by 44% to RMB1,282 million, and its cash position improved to RMB2,917 million. Junshi生物科学组织在其药物管道中也取得了里程碑式的成就,包括美国批准了治疗鼻腔癌的托里帕利马布。 Junshi Biosciences also achieved milestones in its drug pipelines, including the approval of toripalimab in the U.S. for treating nasopharyngeal carcinoma.